POS-264 PATIENT PALATABILITY AND PREFERENCE STUDY OF 3 POTASSIUM BINDERS IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND HYPERKALAEMIA: RATIONALE AND DESIGN OF THE APPETIZE STUDY

• G. JAMES,
• H. Søndergaard,
• K. Hedman,
• N. Karlsson,
• E. Wittbrodt,
• I. Sabir,
• J. Kim,
• R. Allgren,
• G. Stjernlöf,
• M. Någård,
• H.L. Chung,
• J. Morris,
• D.C. Wheeler

Affiliations

G. JAMES

AstraZeneca, None, Cambridge, United Kingdom

H. Søndergaard

Danish Kidney Association, None, Taastrup, Denmark

K. Hedman

AstraZeneca, None, Gothenburg, Sweden

N. Karlsson

AstraZeneca, None, Gothenburg, Sweden

E. Wittbrodt

AstraZeneca, None, Gaithersburg, United States

I. Sabir

AstraZeneca, None, Cambridge, United Kingdom

J. Kim

AstraZeneca, None, Gaithersburg, United States

R. Allgren

AstraZeneca, None, Gaithersburg, United States

G. Stjernlöf

AstraZeneca, None, Gothenburg, Sweden

M. Någård

AstraZeneca, None, Gaithersburg, United States

H.L. Chung

AstraZeneca, None, Taipei City, Taiwan

J. Morris

AdSAM- University of Florida, None, Gainesville, United States

D.C. Wheeler

University College London, Department of Renal Medicine, London, United Kingdom